Clinical Trial Update: Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pioglitazone hydrochloride in patients with stage I-IIIA non-small cell lung cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pioglitazone hydrochloride (Pioglitazone hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2015-10-06